目的 观察核黄素磷酸钠联合干扰素治疗小儿疱疹性咽峡炎的疗效。方法 选取2012年10月—2015年4月重庆市沙坪坝区妇幼保健计划生育服务中心收治的疱疹性咽峡炎患儿100例,随机分为对照组和治疗组,每组各50例。两组患者均给予物理或药物降温、补液支持、抗菌素治疗等常规治疗。对照组在此基础上雾化吸入重组人干扰素α1b注射液,6个月~1岁6 μg/次,1~3岁10 μg/次,3岁以上20 μg/次,1次/d。治疗组在对照组基础上静脉滴注稀释后的核黄素磷酸钠5~10 mg,1次/d。观察两组患者的临床疗效,并比较两组患者疱疹溃疡消失时间、流涎消失时间、退热时间、住院时间和不良反应。结果 治疗后,对照组和治疗组总有效率分别为76.0%、88.0%,两组比较差异具有统计学意义(P<0.05)。治疗组患者疱疹溃疡消失时间、流涎消失时间、退热时间、住院时间均低于对照组,两组比较差异具有统计学意义(P<0.05)。对照组和治疗组不良反应发生率分别为20.0%、8.0%,两组比较差异具有统计学意义(P<0.05)。结论 核黄素磷酸钠联合干扰素治疗小儿疱疹性咽峡炎具有较好的临床疗效,可缩短疱疹溃疡消失时间、流涎消失时间、退热时间、住院时间,不良反应少,具有一定的临床推广应用价值。

Objective To observe the clinical effect of riboflavin sodium phosphate combined with interferon in the treatment of children herpangina. Methods Patients (100 cases) with herpangina in Maternal and Child Health Care Family Planning Service Center of Shapingba District of Chongqing from October 2012 to April 2015 were randomly divided into control and treatment groups, and each group had 50 cases. All patients were given conventional treatment including physical or drugs cooling, rehydration support and antibiotic therapy. The patients in the control group were iv administered with Recombinant Human Interferon α1b Injection on the basis of conventional treatment, once daily. The amounts of drugs were corresponding with ages of children, such as 6 months—1 year children had 6 μg/time, 1—3 years children had 10 μg/time, but above 3 years children had 20 μg/time. The patients in the treatment group were iv administered with Riboflavin Sodium Phosphate Injection on the basis of the control group, 5—10 mg, once daily. The clinical efficacies of the two groups were observed, and time of herpetic ulcer dissipated, salivation dissipated, cooling and hospitalization, and adverse reactions were compared between two groups. Results After treatment, the clinical efficacies in the control and treatment groups were 76.0% and 88.0%, respectively, and there were differences between two groups (P< 0.05). Compared with control group, time of herpetic ulcer dissipated, salivation dissipated, cooling and hospitalization of patients in treatment group were lower, and there were differences between two groups (P< 0.05). The incidence of adverse reactions in the control and treatment groups were 20.0% and 8.0%, respectively, and there were differences between two groups (P< 0.05). Conclusion Riboflavin sodium phosphate combined with interferon has clinical curative effect in the treatment of children herpangina, can reduce time of herpetic ulcer dissipated, salivation dissipated, cooling and hospitalization of patients, and incidence of adverse reactions is few, which has a certain clinical application value.